Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Respiratory System

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43865   clinical trials with a EudraCT protocol, of which   7286   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    753 result(s) found for: Respiratory System. Displaying page 1 of 38.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2011-005029-31 Sponsor Protocol Number: P110102 Start Date*: Information not available in EudraCT
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title:
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10038683 Respiratory disorder PT
    Population Age: Children, Under 18 Gender:
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002261-38 Sponsor Protocol Number: P100504 Start Date*: Information not available in EudraCT
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title:
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10038683 Respiratory disorder PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2012-000775-17 Sponsor Protocol Number: PI11-0143 Start Date*: 2012-11-21
    Sponsor Name:Jesús Villar Hernández
    Full Title: A comparative, randomised controlled trial for evaluating the efficacy of dexamethasone administration in the treatment of patients with the Acute Respiratory Distress Syndrome
    Medical condition: Acute respiratory distress syndrome (ARDS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001052 Acute respiratory distress syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005883-78 Sponsor Protocol Number: CHRD1520 Start Date*: 2021-02-05
    Sponsor Name:Hospital Center rené Dubos
    Full Title: Comparison of Prednisolone and Dexamethasone on D28 mortality in patients on oxygen therapy with CoViD-19
    Medical condition: Care of severe forms of CoViD-19 from the transitional phase and the onset of the inflammatory phase with corticosteroids
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084270 SARS-CoV-2 acute respiratory disease LLT
    23.0 10021881 - Infections and infestations 10084272 SARS-CoV-2 infection LLT
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    21.1 100000004855 10042839 Syndrome respiratory distress adult LLT
    23.1 10021881 - Infections and infestations 10084401 COVID-19 respiratory infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-014301-14 Sponsor Protocol Number: 2009-014301-14 Start Date*: 2009-07-15
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Farmacologic prevention with Varenicline in heavy smokers undergoing early detection lung cancer screening
    Medical condition: Heavy smokers with higher risk in developing lung cancer and smoke related diseases
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038738 SOC
    9.1 10038716 HLGT
    9.1 10029107 HLGT
    9.1 10006334 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-005365-39 Sponsor Protocol Number: OR00213 Start Date*: 2014-03-20
    Sponsor Name:Research in Real-Life Ltd
    Full Title: A guideline approach to therapy step-down utilising Flutiform®: change and step-down (FFLU-X study)
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    16.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    16.1 10038738 - Respiratory, thoracic and mediastinal disorders 10038683 Respiratory disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-001675-33 Sponsor Protocol Number: VPM1002-DE-3.07CoV Start Date*: 2020-05-29
    Sponsor Name:Vakzine Projekt Management GmbH
    Full Title: A phase III, randomized, double-blind, placebo-controlled, multicentre, clinical trial to assess the efficacy and safety of VPM1002 in reducing hospital admissions and/or severe respiratory infecti...
    Medical condition: infectious respiratory diseases (e.g. COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10024970 Respiratory tract infections HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-002156-42 Sponsor Protocol Number: MB 1206/1770/04 Start Date*: 2007-11-22
    Sponsor Name:VALEAS
    Full Title: Effects of Treatment with Cefaclor in acute pharyngotonsillitis and activity on the immune system
    Medical condition: Acute pharyngotonsillitis
    Disease: Version SOC Term Classification Code Term Level
    6.1 10062352 PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003923-40 Sponsor Protocol Number: APHP200019 Start Date*: 2021-01-08
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS ( AP-HP)
    Full Title: A Multicentre Concealed‐Allocation Parallel‐Group Blinded Randomized Controlled Trial to Ascertain the Effect of High‐Dose Intravenous Vitamin C Compared to Placebo on Mortality or Persistent Organ...
    Medical condition: Sepsis complicated by ARDS
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001052 Acute respiratory distress syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021092-89 Sponsor Protocol Number: SICOG1001 Start Date*: 2011-04-07
    Sponsor Name:SOUTHERN ITALY COOPERATIVE ONCOLOGY GROUP
    Full Title: Cisplatin and Alimta with panitumumaB for Advanced non-squamous Lung cAncer (CABALA Trial): a SICOG multicenter, phase II trial
    Medical condition: previously untreated, EGFR + (FISH), advanced, non-squamous, NSCLC
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029107 HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-004706-22 Sponsor Protocol Number: ImlifidARDSe.01 Start Date*: 2023-02-17
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Imlifidase in ANCA-associated vasculitis
    Medical condition: Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis with severe diffuse alveolar hemorrhage
    Disease: Version SOC Term Classification Code Term Level
    21.1 10047065 - Vascular disorders 10072579 Granulomatosis with polyangiitis PT
    21.1 10047065 - Vascular disorders 10063344 Microscopic polyangiitis PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001052 Acute respiratory distress syndrome PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037314 Pulmonary alveolar hemorrhage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001302-30 Sponsor Protocol Number: ACOVACT Start Date*: 2020-04-15
    Sponsor Name:Medical University of Vienna
    Full Title: A multicenter, randomized, active controlled, open label, platform trial on the efficacy and safety of experimental therapeutics for patients with COVID-19 (caused by infection with severe acute re...
    Medical condition: Infection with SARS-COV-2 (=COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10035737 Pneumonia viral PT
    21.1 100000004855 10003083 ARDS LLT
    20.0 10021881 - Infections and infestations 10038700 Respiratory infection LLT
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000753-28 Sponsor Protocol Number: 212494 Start Date*: 2021-05-05
    Sponsor Name:GlaxoSmithKline Biologicals SA
    Full Title: A Phase 3, randomized, placebo-controlled, observer-blind, multi-country study to demonstrate the efficacy of a single dose and annual revaccination of GSK’s RSVPreF3 OA investigational vaccine in ...
    Medical condition: Respiratory Syncytial Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10035732 Pneumonia respiratory syncytial viral PT
    21.1 10021881 - Infections and infestations 10038718 Respiratory syncytial virus bronchiolitis PT
    21.1 10021881 - Infections and infestations 10069811 Respiratory syncytial virus bronchitis PT
    21.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    21.1 10021881 - Infections and infestations 10035692 Pneumonia due to respiratory syncytial virus LLT
    21.1 10021881 - Infections and infestations 10067384 Respiratory syncytial virus pneumonitis LLT
    21.1 10021881 - Infections and infestations 10052200 Respiratory syncytial virus infection NOS LLT
    21.1 10021881 - Infections and infestations 10066741 Respiratory syncytial virus infection recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Ongoing) DE (Ongoing) IT (Ongoing) SE (Prematurely Ended) HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001244-26 Sponsor Protocol Number: COV-2-SOLNATIDE-20 Start Date*: 2020-04-11
    Sponsor Name:Department of Clinical Pharmacology, Medical University of Vienna, Vienna Austria
    Full Title: COVID-19: Efficacy of solnatide to treat pulmonary permeability oedema in SARS-Cov-2 positive patients with moderate-to-severe ARDS - a pilot-trial.
    Medical condition: Pulmonary permeability oedema in SARS-Cov-2 positive patients with moderate-to-severe ARDS
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003083 ARDS LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037423 Pulmonary oedema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001760-31 Sponsor Protocol Number: J0022XST302 Start Date*: 2013-07-04
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: Clinical efficacy and safety of J022X ST in the prevention of Recurrent Upper-Respiratory Tract Infections (RURTI) in children with a high risk of recurrence
    Medical condition: Recurrent Upper-Respiratory Tract Infections (RURTI)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10046306 Upper respiratory tract infection PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) LT (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2019-004680-51 Sponsor Protocol Number: 212496 Start Date*: 2021-01-18
    Sponsor Name:GlaxoSmithKline Biologicals SA
    Full Title: A phase 3, randomized, open-label, multi-country study to evaluate the immunogenicity, safety, reactogenicity and persistence of a single dose of the RSVPreF3 OA investigational vaccine and differe...
    Medical condition: Healthy volunteers (Active immunization for the prevention of disease caused by RSV in adults aged 60 years or above)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10035732 Pneumonia respiratory syncytial viral PT
    21.1 10021881 - Infections and infestations 10038718 Respiratory syncytial virus bronchiolitis PT
    21.1 10021881 - Infections and infestations 10069811 Respiratory syncytial virus bronchitis PT
    21.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    21.1 10021881 - Infections and infestations 10035692 Pneumonia due to respiratory syncytial virus LLT
    21.1 10021881 - Infections and infestations 10067384 Respiratory syncytial virus pneumonitis LLT
    21.1 10021881 - Infections and infestations 10052200 Respiratory syncytial virus infection NOS LLT
    21.1 10021881 - Infections and infestations 10066741 Respiratory syncytial virus infection recurrent LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Ongoing) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-001671-35 Sponsor Protocol Number: MI-CP124 Start Date*: 2005-08-16
    Sponsor Name:MedImmune, Inc.
    Full Title: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), in Childr...
    Medical condition: Serious respiratory syncytial virus (RSV) disease in children with hemodynamically significant congential heart disease (CHD).
    Disease: Version SOC Term Classification Code Term Level
    7.0 10061603 PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) SE (Completed) CZ (Prematurely Ended) BE (Completed) DE (Completed) DK (Completed) AT (Prematurely Ended) ES (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-002567-57 Sponsor Protocol Number: 1.0 Start Date*: 2020-11-23
    Sponsor Name:University of Oxford / Clinical Trials and Research Governance
    Full Title: To determine whether administration of almitrine bismesylate can ameliorate hypoxaemia in Covid-19 and augment effectiveness of supplementary oxygen therapy and respiratory support
    Medical condition: Covid-19
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001053 Acute respiratory failure PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2017-003855-47 Sponsor Protocol Number: AP301-II-002 Start Date*: 2018-02-27
    Sponsor Name:Apeptico Forschung und Entwicklung GmbH
    Full Title: Safety and preliminary efficacy of sequential multiple ascending doses of solnatide to treat pulmonary permeability oedema in patients with moderate-to-severe ARDS - a randomised, placebo-controlle...
    Medical condition: pulmonary permeability oedema in patients with moderate-to-severe ARDS
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003083 ARDS LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037423 Pulmonary oedema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-006427-18 Sponsor Protocol Number: 2021.143 Start Date*: 2022-08-26
    Sponsor Name:Anna Coquard Rafales
    Full Title: M-POC-O2: high flow nasal cannula oxygen versus conventional oxygen therapy in exacerbated chronic obstructive pulmonary disease (COPD) patients without respiratory acidosis. Pilot Study.
    Medical condition: Patients older than 35 years old with COPD diagnosis (chronic obstructive pulmonary disease) by spirometry, presenting acute exacerbation without respiratory acidosis.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Apr 27 09:37:33 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA